Merck seeks to switch Singulair for allergies

10 April 2014 - Deborah Wilkes

Archived

Merck & Co is seeking to switch Singulair (montelukast) from prescription-only to OTC status in the US as an allergy remedy but not an asthma treatment.

Click tags below for more information on topics:

FDA

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: